SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

VK3019

VKTX·Viking Therapeutics, Inc
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / Early-stage (no confirmed Phase 1/2 clinical trials identified)
Time to market
Not stated
Why 2/10
VK3019 is an early-stage/preclinical asset with no scheduled near-term binary catalyst (no PDUFA, no confirmed Phase 2/3 readout) in the next 12 months. The company's value is dominated by its lead asset VK2735 (Phase 3 obesity), making VK3019 a minor pipeline component. ImpactScore is 2 per the rubric for a preclinical/minor program with no scheduled catalyst.
Actionable Insight NEUTRAL

VK3019 is preclinical/early-stage and not the company's primary value driver, investors should watch Viking's lead asset VK2735 (Phase 3 obesity) for near-term stock movement. VK3019 updates would most likely come via Viking's R&D day or quarterly earnings calls. The next company catalyst is Q3 2026 earnings on October 28, 2026, where pipeline updates on both VK2735 and VK3019 may be discussed.

Price Chart

Loading chart...

Executive Summary

VK3019 is an amylin agonist being developed by Viking Therapeutics (NASDAQ: VKTX) for the treatment of obesity and metabolic disorders. It is an early-stage/preclinical asset, the second pipeline program behind the company's lead drug VK2735 (a GLP-1/GIP dual agonist already in Phase 3 trials). In September 2026, Viking raised approximately $534 million through a combined stock and convertible note offering, specifically earmarking proceeds to fund both VK2735 commercialization and VK3019 advancement. VK3019 has no upcoming near-term binary catalyst (no PDUFA date, no confirmed Phase 2/3 readout), and the company's stock value is currently dominated by VK2735's Phase 3 obesity program. Analyst consensus on VKTX is Strong Buy with a mean price target of ~$95, but the stock has declined to ~$24.40 after the dilutive capital raise.

How It Works

VK3019 is an amylin agonist, a drug that mimics the natural hormone amylin, which is co-secreted with insulin after meals. Amylin slows gastric emptying (makes food leave the stomach more slowly), promotes a feeling of fullness (satiety), and helps regulate blood sugar. The mechanism is complementary to GLP-1 agonists like Ozempic/Wegovy, while GLP-1 drugs boost insulin secretion, amylin agonists target different satiety pathways, potentially offering additive weight loss or better tolerability when combined.

Trial Status

VK3019 is an early-stage development program. No specific clinical trial data appears in public registries/updates. The SEC filing from September 2026 states that capital raised will fund "continued clinical development" of VK2735 and "advancement" of VK3019, suggesting the program has not yet entered pivotal-stage clinical trials. The company's lead program VK2735 (oral formulation) initiated Phase 3 trials (SUNRISE-1 and SUNRISE-2) in October 2026.

The Two-Sided Case

▲ Bull Case4
Amylin agonists represent a differentiated mechanism in obesity, amylin promotes satiety, complements GLP-1 agonism, and could offer weight loss with fewer gastrointestinal side effects or be used as a combination agent.
Viking's lead asset VK2735 (GLP-1/GIP dual agonist) has shown strong Phase 2/3 data, validating the company's metabolic drug discovery platform, success could derisk VK3019 as a pipeline-in-progression story.
Viking raised ~$534M in September 2026 specifically to fund VK3019 development alongside VK2735 commercialization, signaling strong institutional confidence in the pipeline.
Analyst consensus on VKTX is Strong Buy (23 Buy/Strong Buy, 3 Hold, 0 Sell) with a mean price target of ~$95, implying ~290% upside from the current ~$24.40 price.
▼ Bear Case4
As an early-stage/preclinical asset, VK3019 has a high probability of never reaching the market, most early-stage metabolic drugs fail in clinical trials.
VK3019 would enter a fiercely competitive obesity market dominated by Novo Nordisk's Wegovy/Ozempic, Eli Lilly's Zepbound/Mounjaro, and numerous other amylin and GLP-1 agonists in development.
Viking has no approved products and is pre-revenue, any VK3019 development costs are fully funded by equity/debt raises that dilute existing shareholders, as seen in the Sep 2026 ~$534M capital raise.
The stock has been under significant pressure, trading at ~$24.40, down from its 52-week high of $43.15, and technical indicators are bearish (sell signal, -32 composite score, price below all major SMAs).

Upcoming Catalysts

  • Q3 2026 earnings call (October 28, 2026), possible pipeline update on VK3019
  • Any early clinical data readout for VK3019 (no date confirmed)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 prnewswire.com4 prnewswire.com5 prnewswire.com